Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy

American Journal of Therapeutics

Volumn 19, Issue 1, 2012, Pages 24-32

  Rublee, Dale A ^a   Chen, Shih Yin ^b   Mardekian, Jack ^a   Wu, Ning ^b   Rao, Preethi ^b   Boulanger, Luke ^b  

^a PFIZER INC   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

adherence; atorvastatin; cardiovascular risk; healthy adherer effect

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEOPLASM; OBESITY; PATIENT COMPLIANCE; PHARMACY; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; PYRROLES; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855641607     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181ee707e     Document Type: Article

References (31)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121: e46-e215.
2. Nichols GA, Bell TJ, Pedula KL, et al. Medical care costs among patients with established cardiovascular disease. Am J Manag Care. 2010;16:e86-e93.
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis. BMJ. 2003;326:1423-1427. (Pubitemid 36776152)
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
5. Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther. 2009;31: 236-244.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
8. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
9. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435. (Pubitemid 40471450)
10. Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002;113:625-629. (Pubitemid 36015797)
11. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006;12: S405-S411. (Pubitemid 44865051)
12. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462. (Pubitemid 28228203)
13. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467. (Pubitemid 34787477)
14. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19:638-645.
15. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther. 2005;27:1639-1646. (Pubitemid 41739501)
16. Blackburn DF, Dobson RT, Blackburn JL, et al. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25:1035-1043. (Pubitemid 41099437)
17. Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007;63:698-708. (Pubitemid 46753568)
18. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772-779. (Pubitemid 351410514)
19. Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad Med. 2010;122:16-24.
20. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166:348-354. (Pubitemid 47216808)
21. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119:2051-2057.
22. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28:1411-1424. (Pubitemid 44585292)
23. Vink NM, Klungel OH, Stolk RP, et al. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf. 2009;18:159-165.
24. Shah ND, Dunlay SM, Ting HH, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009;122:961 e7-e13.
25. Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009;12:489-497.
26. Bates TR, Connaughton VM,Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10:2973-2985.
27. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48:196-202.
28. Piette JD, Heisler M, Krein S, et al. The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med. 2005;165: 1749-1755. (Pubitemid 41138963)
29. Rickles NM, Svarstad BL, Statz-Paynter JL, et al. Pharmacist telemonitoring of antidepressant use: effects on pharmacist-patient collaboration. J Am Pharm Assoc. 2005; 45:344-353. (Pubitemid 46037296)
30. Casebeer L, Huber C, Bennett N, et al. Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009;10:48.
31. Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc. 2003;43:668-678.